$CATX
Perspective Therapeutics, Inc. Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-K Financial Statement

#000114420414058408 Filed on September 29, 2014

Income Statement

Concept	2014 Q3	2013 Q2
Revenue	$1.042M	$1.240M
YoY Change	-0.74%	-5.34%
Cost Of Revenue	$1.097M	$1.100M
YoY Change	-2.69%	1.85%
Gross Profit	-$54.80K	$140.0K
YoY Change	-29.11%	-39.13%
Gross Profit Margin	-5.26%	11.29%
Selling, General & Admin	$929.7K	$980.0K
YoY Change	-7.97%	-3.92%
% of Gross Profit		700.0%
Research & Development	$176.6K	$180.0K
YoY Change	20.15%	-14.29%
% of Gross Profit		128.57%
Depreciation & Amortization	$170.0K	$190.0K
YoY Change	-10.54%	-26.92%
% of Gross Profit		135.71%
Operating Expenses	$1.106M	$1.160M
YoY Change	-4.4%	-0.85%
Operating Profit	-$1.161M	-$1.020M
YoY Change	-5.95%	8.51%
Interest Expense	$3.451K	$30.00K
YoY Change	365.72%	-111.54%
% of Operating Profit
Other Income/Expense, Net	$375.2K
YoY Change	-1131.26%
Pretax Income	-$790.0K	-$990.0K
YoY Change	-37.8%	-17.5%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$785.9K	-$990.0K
YoY Change	-38.17%	-17.5%
Net Earnings / Revenue	-75.41%	-79.84%
Basic Earnings Per Share
Diluted Earnings Per Share	-$14.40K	-$28.60K
COMMON SHARES
Basic Shares Outstanding	54.88M shares	34.61M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.10M	$2.900M
YoY Change	129.17%	8.61%
Cash & Equivalents	$2.075M	$2.900M
Short-Term Investments	$10.03M
Other Short-Term Assets	$250.0K	$26.69K
YoY Change	19.05%	0.0%
Inventory	$407.5K	$405.6K
Prepaid Expenses
Receivables	$962.3K	$923.8K
Other Receivables	$5.258K	$11.50K
Total Short-Term Assets	$13.73M	$4.444M
YoY Change	98.89%	7.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$855.4K	$1.684M
YoY Change	-43.35%	-30.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.05M
YoY Change
Other Assets	$258.6K	$276.5K
YoY Change	-4.7%	-8.35%
Total Long-Term Assets	$11.81M	$2.612M
YoY Change	385.61%	-22.49%
TOTAL ASSETS
Total Short-Term Assets	$13.73M	$4.444M
Total Long-Term Assets	$11.81M	$2.612M
Total Assets	$25.54M	$7.055M
YoY Change	173.6%	-6.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$510.0K	$430.0K
YoY Change	-21.54%	10.26%
Accrued Expenses	$470.0K	$360.0K
YoY Change	46.88%	38.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$979.1K	$792.9K
YoY Change	0.94%	22.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.140M	$900.0K
YoY Change	20.0%	-13.46%
Total Long-Term Liabilities	$1.140M	$900.0K
YoY Change	20.0%	-13.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$979.1K	$792.9K
Total Long-Term Liabilities	$1.140M	$900.0K
Total Liabilities	$2.115M	$1.689M
YoY Change	10.16%	0.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.84M	-$52.09M
YoY Change	10.26%	8.0%
Common Stock	$54.88K	$34.62K
YoY Change	42.85%	11.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$8.390K	$8.390K
YoY Change	0.0%	0.0%
Treasury Stock Shares	13.20K shares	13.20K shares
Shareholders Equity	$23.42M	$5.366M
YoY Change
Total Liabilities & Shareholders Equity	$25.54M	$7.055M
YoY Change	173.6%	-6.0%

Cashflow Statement

Concept	2014 Q3	2013 Q2
OPERATING ACTIVITIES
Net Income	-$785.9K	-$990.0K
YoY Change	-38.17%	-17.5%
Depreciation, Depletion And Amortization	$170.0K	$190.0K
YoY Change	-10.54%	-26.92%
Cash From Operating Activities	-$1.140M	-$790.0K
YoY Change	27.8%	25.4%
INVESTING ACTIVITIES
Capital Expenditures	$7.453K	$0.00
YoY Change	265.16%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$4.670M	$0.00
YoY Change
Cash From Investing Activities	-$4.680M	$0.00
YoY Change	100958.09%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	220.0K	10.00K
YoY Change	-93.29%	-98.73%
NET CHANGE
Cash From Operating Activities	-1.140M	-790.0K
Cash From Investing Activities	-4.680M	0.000
Cash From Financing Activities	220.0K	10.00K
Net Change In Cash	-5.600M	-780.0K
YoY Change	-334.88%	-700.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.140M	-$790.0K
Capital Expenditures	$7.453K	$0.00
Free Cash Flow	-$1.147M	-$790.0K
YoY Change	28.34%	31.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	3043707	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2233670	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.02
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54883445	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q4	dei	Entity Public Float EntityPublicFloat	19025956	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	IsoRay, Inc.
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	isr	Class Of Warrant Or Right Corrected ClassOfWarrantOrRightCorrected	26939	shares
CY2013	isr	Class Of Warrant Or Right Corrected ClassOfWarrantOrRightCorrected		shares
CY2014	isr	Class Of Warrant Or Right Corrected In Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightCorrectedInPeriodExercisePriceOfWarrantsOrRights	1.31
CY2013	isr	Class Of Warrant Or Right Corrected In Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightCorrectedInPeriodExercisePriceOfWarrantsOrRights
CY2014	isr	Class Of Warrant Or Right Expired In Period ClassOfWarrantOrRightExpiredInPeriod	22520	shares
CY2013	isr	Class Of Warrant Or Right Expired In Period ClassOfWarrantOrRightExpiredInPeriod		shares
CY2014	isr	Class Of Warrant Or Right Expired In Period Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExpiredInPeriodWeightedAverageExercisePriceOfWarrantsOrRights	0.96
CY2013	isr	Class Of Warrant Or Right Expired In Period Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExpiredInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
CY2014	isr	Class Of Warrant Or Right Grants In Period ClassOfWarrantOrRightGrantsInPeriod	5648738	shares
CY2013	isr	Class Of Warrant Or Right Grants In Period ClassOfWarrantOrRightGrantsInPeriod		shares
CY2014	isr	Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePriceOfWarrantsOrRights	0.72
CY2013	isr	Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
CY2014	isr	Class Of Warrant Or Right Issued In Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightIssuedInPeriodExercisePriceOfWarrantsOrRights	0.86
CY2013	isr	Class Of Warrant Or Right Issued In Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightIssuedInPeriodExercisePriceOfWarrantsOrRights	0.66
CY2014Q2	isr	Commitment Cpi CommitmentCpi	0.011	pure
CY2014	isr	Distribution Agreement Renewal Notice DistributionAgreementRenewalNotice	P30D
CY2013Q3	isr	Gross Proceeds From Issuance Of Stock GrossProceedsFromIssuanceOfStock	3703527	USD
CY2014Q1	isr	Gross Proceeds From Issuance Of Stock GrossProceedsFromIssuanceOfStock	14675180	USD
CY2014	isr	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	-483747	USD
CY2013	isr	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	73500	USD
CY2014	isr	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	13814742	USD
CY2013	isr	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	3291977	USD
CY2014	isr	Issuance Of Common Stock In Connection With Warrant Exercises Net Of Issuance Costs Shares IssuanceOfCommonStockInConnectionWithWarrantExercisesNetOfIssuanceCostsShares	7165443	shares
CY2013	isr	Issuance Of Common Stock In Connection With Warrant Exercises Net Of Issuance Costs Shares IssuanceOfCommonStockInConnectionWithWarrantExercisesNetOfIssuanceCostsShares	2766	shares
CY2014	isr	Noncash Investing And Financing Item Deemed Preferred Stock Dividend NoncashInvestingAndFinancingItemDeemedPreferredStockDividend	726378	USD
CY2013	isr	Noncash Investing And Financing Item Deemed Preferred Stock Dividend NoncashInvestingAndFinancingItemDeemedPreferredStockDividend		USD
CY2014	isr	Noncash Investing And Financing Items NoncashInvestingAndFinancingItems	3118215	USD
CY2013	isr	Noncash Investing And Financing Items NoncashInvestingAndFinancingItems		USD
CY2014	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification	913134	USD
CY2013	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification		USD
CY2014Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	574855	USD
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	432566	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	913049	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	923780	USD
CY2014Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	120765	USD
CY2013Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	107578	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6548815	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5923142	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81959853	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57431293	USD
CY2014	us-gaap	Adjustment For Amortization AdjustmentForAmortization	30189	USD
CY2013	us-gaap	Adjustment For Amortization AdjustmentForAmortization	31302	USD
CY2013Q3	isr	Payments For Underwriting Fees Costs PaymentsForUnderwritingFeesCosts	185176	USD
CY2014Q1	isr	Payments Of Stock Issuance Costs Commission Expense PaymentsOfStockIssuanceCostsCommissionExpense	733759	USD
CY2013Q3	isr	Payments Of Stock Issuance Costs Legal And Accounting Expense PaymentsOfStockIssuanceCostsLegalAndAccountingExpense	184514	USD
CY2014Q1	isr	Payments Of Stock Issuance Costs Legal And Accounting Expense PaymentsOfStockIssuanceCostsLegalAndAccountingExpense	76679	USD
CY2013Q3	isr	Payments Of Stock Issuance Costs Listing Expense PaymentsOfStockIssuanceCostsListingExpense	48500	USD
CY2014Q1	isr	Payments Of Stock Issuance Costs Listing Expense PaymentsOfStockIssuanceCostsListingExpense	45000	USD
CY2013Q3	isr	Payments Of Stock Issuance Costs Other Expenses PaymentsOfStockIssuanceCostsOtherExpenses	6045	USD
CY2014Q1	isr	Payments Of Stock Issuance Costs Other Expenses PaymentsOfStockIssuanceCostsOtherExpenses	5000	USD
CY2014	isr	Preferred Stock Issued During Period Value New Issues PreferredStockIssuedDuringPeriodValueNewIssues	1478703	USD
CY2014	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	13992	USD
CY2013	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	5006	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	185987	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	108351	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	185987	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	108351	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	38607	USD
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	52598	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18468	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19581	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2818234	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4321170	shares
CY2014Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	866560	USD
CY2012Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	724298	USD
CY2013Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	792242	USD
CY2007Q3	us-gaap	Asset Retirement Obligation AssetRetirementObligation	473096	USD
CY2014	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	74318	USD
CY2013	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	67944	USD
CY2014Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	866560	USD
CY2013Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	792242	USD
CY2014Q2	us-gaap	Assets Assets	26549255	USD
CY2013Q2	us-gaap	Assets Assets	7055356	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	19214900	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	4443660	USD
CY2005Q3	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	0.82	pure
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7680073	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2672711	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2899927	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4780146	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	227216	USD
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.43
CY2014	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1478703	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		USD
CY2014	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		USD
CY2012Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.38
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.38
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	444747	shares
CY2012Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1959799	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1957033	shares
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	192998329	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	193000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54701708	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34618517	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54701708	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34618517	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38419502	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41540982	shares
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	54702	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	34618	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4415629	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4375057	USD
CY2014Q2	us-gaap	Deferred Costs DeferredCosts	40320	USD
CY2013Q2	us-gaap	Deferred Costs DeferredCosts	61331	USD
CY2014Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18447161	USD
CY2013Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15798912	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2013Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2014Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17274297	USD
CY2013Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14791279	USD
CY2014Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	446998	USD
CY2013Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	408223	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	371358	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	279089	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations	303296	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations	277285	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	13512	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	18409	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	37700	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	24627	USD
CY2014Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18447161	USD
CY2013Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15798912	USD
CY2014	us-gaap	Depreciation Depreciation	685396	USD
CY2013	us-gaap	Depreciation Depreciation	739147	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	685396	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	739147	USD
CY2014Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	573000	USD
CY2013Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	104000	USD
CY2014	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	10632	USD
CY2013	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	10632	USD
CY2013Q2	us-gaap	Due From Employees Noncurrent DueFromEmployeesNoncurrent	2938	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	236282	USD
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	127419	USD
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	340497	USD
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M4D
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	109292	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	90824	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	131303	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	20709	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	16088	USD
CY2014	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	41592	USD
CY2013	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	48000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	16238	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	18709	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	20709	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	223756	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	215176	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2488219	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2294173	USD
CY2014	us-gaap	Gross Profit GrossProfit	-196471	USD
CY2013	us-gaap	Gross Profit GrossProfit	150176	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2512481	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1257494	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2039240	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1349809	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	10209	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	17966	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	297	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	849	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	142289	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	43461	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-24723	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	53718	USD
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	108863	USD
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	7538	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-45834	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-38774	USD
CY2014	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	55128	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	25305	USD
CY2014	us-gaap	Interest And Debt Expense InterestAndDebtExpense	883	USD
CY2013	us-gaap	Interest And Debt Expense InterestAndDebtExpense	7	USD
CY2014	us-gaap	Interest Paid InterestPaid	748	USD
CY2013	us-gaap	Interest Paid InterestPaid	7	USD
CY2014	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	13187	USD
CY2013	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	19572	USD
CY2014	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	41580	USD
CY2013	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1577	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3167	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	58764	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	59	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	122	USD
CY2014Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	34999	USD
CY2013Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	42577	USD
CY2014Q2	us-gaap	Inventory Net InventoryNet	359737	USD
CY2013Q2	us-gaap	Inventory Net InventoryNet	405571	USD
CY2014Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	469758	USD
CY2013Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	469758	USD
CY2014Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	173417	USD
CY2013Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	167671	USD
CY2014Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	151321	USD
CY2013Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	195323	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	12113	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	664	USD
CY2014	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	114313	USD
CY2013	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	86705	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23449523	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3296299	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-15441156	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-12816	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	276395	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	284097	USD
CY2014Q2	us-gaap	Liabilities Liabilities	2593487	USD
CY2013Q2	us-gaap	Liabilities Liabilities	1689110	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26549255	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7055356	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1153927	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	792868	USD
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"> </td> <td style="WIDTH: 0.25in"><strong>1.</strong></td> <td style="TEXT-ALIGN: justify"><strong>Organization</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; TEXT-INDENT: -0.25in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Century Park Pictures Corporation (Century) was organized under Minnesota law in 1983. Century had no operations during the period from September 30, 1999 through June 30, 2005.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> On July 28, 2005, IsoRay Medical, Inc. (Medical) became a wholly-owned subsidiary of Century pursuant to a merger. Century changed its name to IsoRay, Inc. (IsoRay or the Company). In the merger, the Medical stockholders received approximately 82% of the then outstanding securities of the Company.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Medical, a Delaware corporation, was incorporated effective June 15, 2004 to develop, manufacture and sell isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Medical is headquartered in Richland, Washington.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> IsoRay International LLC, a Washington limited liability company, which is wholly-owned by IsoRay Inc. was formed on November 27, 2007 to serve as an owner in a Russian LLC that planned to distribute the Company's products to the Russian market and also license the Company's technology for use in manufacturing Cs-131 brachytherapy seeds in Russia.  During fiscal year 2009, the Company divested its ownership in the Russian LLC. The entity is utilized to conduct business with the international distributors of its products.</p> <!--EndFragment--></div> </div>
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3228221	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3056267	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-5959122	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-3856596	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6696132	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3867228	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1339916	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	277224	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	231020	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1370904	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	210657	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	4391747	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	4217429	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-4588218	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-4067253	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	277224	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	277224	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	277224	USD
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	80433	USD
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	25305	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	26693	USD
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	26693	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	264076	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	276507	USD
CY2007Q2	us-gaap	Other Inventory Purchased Goods OtherInventoryPurchasedGoods	469758	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	141592	USD
CY2013Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	100000	USD
CY2014Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	5401398	USD
CY2013Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments		USD
CY2014Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	131890	USD
CY2013Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	105347	USD
CY2014Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	53082	USD
CY2013Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	11502	USD
CY2014	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
CY2013	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17758	USD
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6118	USD
CY2014	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	5401398	USD
CY2013	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments		USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19029	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6576	USD
CY2014	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	10002912	USD
CY2013	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		USD
CY2014	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	10632	USD
CY2013	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	10632	USD
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	726378	USD
CY2013	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium		USD
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7001671	shares
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7001671	shares
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	59	USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	59	USD
CY2014Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	14124	USD
CY2013Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	10590	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	206047	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	202880	USD
CY2014Q2	us-gaap	Prepaid Insurance PrepaidInsurance	24763	USD
CY2013Q2	us-gaap	Prepaid Insurance PrepaidInsurance	48421	USD
CY2014Q2	us-gaap	Prepaid Rent PrepaidRent	22701	USD
CY2013Q2	us-gaap	Prepaid Rent PrepaidRent	22419	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13814742	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3291977	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3279292	USD
CY2014Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13814742	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	266314	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13129	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6099807	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1825	USD
CY2014	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1478703	USD
CY2013	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		USD
CY2014	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1800589	USD
CY2013	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		USD
CY2014	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	59723	USD
CY2014Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7566730	USD
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7607424	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1017915	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1684282	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	668803	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	627107	USD
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181208	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181149	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58050456	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52091334	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4219158	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4525233	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.09
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	548928	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	16246	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod		shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3186916	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2314422	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2381306	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2305072	shares
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y9M15D
CY2014	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1234725	USD
CY2013	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1296149	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	185987	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	108351	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1864795	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2030064	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.35
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.94
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	19667	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	37534	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	380000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	50000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.00
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.82
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.83
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y8M9D
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	2515578	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1864795	shares
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y7M6D
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.76
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.34
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.61
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.58
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.92
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice	1.00
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
CY2014Q2	us-gaap	Short Term Investments ShortTermInvestments	10002912	USD
CY2013Q2	us-gaap	Short Term Investments ShortTermInvestments		USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	23955768	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	5818192	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	5366246	USD
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	350983	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	38700	shares
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7012941	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1825	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1800589	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	266314	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13129	USD
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	13200	shares
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	13200	shares
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2014	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1382134	USD
CY2013	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	210000	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> <u>Use of Estimates</u></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: -0.25in">  </p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company's fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company's production facilities; inputs used in the calculation of expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted; and the inputs to the Black-Scholes calculation to estimate the fair value of the derivative warrant liability and the related gain or loss. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.</p> <!--EndFragment--></div> </div>
CY2014Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	573000	USD
CY2013Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	104000	USD
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42675158	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34423420	shares

Files In Submission

Name	View Source	Status
0001144204-14-058408-index-headers.html	Edgar Link	pending
0001144204-14-058408-index.html	Edgar Link	pending
0001144204-14-058408.txt	Edgar Link	pending
0001144204-14-058408-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
isr-20140630.xml	Edgar Link	completed
isr-20140630.xsd	Edgar Link	pending
isr-20140630_cal.xml	Edgar Link	unprocessable
isr-20140630_def.xml	Edgar Link	unprocessable
isr-20140630_lab.xml	Edgar Link	unprocessable
isr-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpg12.jpg	Edgar Link	pending
tpg13.jpg	Edgar Link	pending
v389095_10k.htm	Edgar Link	pending
v389095_ex10-80.htm	Edgar Link	pending
v389095_ex10-81.htm	Edgar Link	pending
v389095_ex21-1.htm	Edgar Link	pending
v389095_ex23-1.htm	Edgar Link	pending
v389095_ex31-1.htm	Edgar Link	pending
v389095_ex31-2.htm	Edgar Link	pending
v389095_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics, Inc. Stock $catx

2014 Q3 Form 10-K Financial Statement

#000114420414058408 Filed on September 29, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics, Inc. Stock $catx

2014 Q3 Form 10-K Financial Statement

#000114420414058408 Filed on September 29, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics, Inc. Stock $catx